Copyright © 2012 Mohamed K. Mehasseb and John A. Latimer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. Y. Zhang and J. Wang, “Controversies in the management of endometrial carcinoma,” Obstetrics and Gynecology International, vol. 2010, Article ID 862908, 26 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
2. D. G. Gallup and R. J. Stock, “Adenocarcinoma of the endometrium in women 40 years of age or younger,” Obstetrics and Gynecology, vol. 64, no. 3, pp. 417–420, 1984. View at Scopus
3. H. J. Norris, F. A. Tavassoli, and R. J. Kurman, “Endometrial hyperplasia and carcinoma. Diagnostic considerations,” American Journal of Surgical Pathology, vol. 7, no. 8, pp. 839–847, 1983. View at Scopus
4. E. L. Trimble, L. C. Harlan, L. X. Clegg, and J. L. Stevens, “Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States,” Gynecologic Oncology, vol. 96, no. 3, pp. 741–748, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. W. T. Creasman, et al., “Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer,” International Journal of Gynecology and Obstetrics, vol. 95, supplement 1, pp. S105–S143, 2006.
6. M. E. Randall, V. L. Filiaci, H. Muss et al., “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 36–44, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. M. Singh, R. J. Zaino, V. J. Filiaci, and K. K. Leslie, “Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 106, no. 2, pp. 325–333, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. J. T. Rabban and C. J. Zaloudek, “Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis,” Pathology, vol. 39, no. 1, pp. 125–133, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. D. T. Wheeler, K. A. Bell, R. J. Kurman, and M. E. Sherman, “Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation,” American Journal of Surgical Pathology, vol. 24, no. 6, pp. 797–806, 2000. View at Publisher · View at Google Scholar · View at Scopus
10. “Practice, A.C.o.G., ACOG Committee Opinion No. 356: routine cancer screening,” Obstetrics and Gynecology, vol. 108, no. 6, pp. 1611–1613, 2006.
11. “Practice guidelines: uterine corpus—endometrial cancer. Society of Gynecologic Oncologists Medical Practice Committee,” Oncology, vol. 12, no. 1, pp. 122–126, 1998.
12. A. B. P. Ng, “The cellular detection of endometrial carcinoma and its precursors,” Gynecologic Oncology, vol. 2, no. 2-3, pp. 162–179, 1974. View at Scopus
13. A. B. P. Ng, J. W. Reagan, S. Hawliczek, and B. W. Wentz, “Significance of endometrial cells in the detection of endometrial carcinoma and its precursors,” Acta Cytologica, vol. 18, no. 5, pp. 356–361, 1974. View at Scopus
14. P. K. Zucker, E. J. Kasdon, and M. L. Feldstein, “The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women,” Cancer, vol. 56, no. 9, pp. 2256–2263, 1985. View at Scopus
15. B. DuBeshter, C. Deuel, S. Gillis, C. Glantz, C. Angel, and D. Guzick, “Endometrial cancer: the potential role of cervical cytology in current surgical staging,” Obstetrics and Gynecology, vol. 101, no. 3, pp. 445–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
16. A. G. Siebers, A. L. M. Verbeek, L. F. Massuger, J. M. M. Grefte, and J. Bulten, “Normal appearing endometrial cells in cervical smears of asymptomatic postmenopausal women have predictive value for significant endometrial pathology,” International Journal of Gynecological Cancer, vol. 16, no. 3, pp. 1069–1074, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. F. P. Dijkhuizen, B. W. Mol, H. A. Brlmann, and A. Heintz, “The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis,” Cancer, vol. 89, no. 8, pp. 1765–1772, 2000. View at Publisher · View at Google Scholar
18. C. D. Runowicz, “Gynecologic surveillance of women on tamoxifen: first do no harm,” Journal of Clinical Oncology, vol. 18, no. 20, pp. 3457–3458, 2000. View at Scopus
19. “American College of, O. and P. Gynecologists Committee on Gynecologic, ACOG committee opinion. No. 336: tamoxifen and uterine cancer,” Obstetrics and Gynecology, vol. 107, no. 6, pp. 1475–1478, 2006.
20. K. H. Lu, M. Dinh, W. Kohlmann et al., “Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome,” Obstetrics and Gynecology, vol. 105, no. 3, pp. 569–574, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. P. Watson and H. T. Lynch, “Extracolonic cancer in hereditary nonpolyposis colorectal cancer,” Cancer, vol. 71, no. 3, pp. 677–685, 1993. View at Publisher · View at Google Scholar
22. M. J. W. Berends, Y. Wu, R. H. Sijmons et al., “Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4364–4370, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
23. K. M. Schmeler, H. T. Lynch, L. M. Chen et al., “Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome,” The New England Journal of Medicine, vol. 354, no. 3, pp. 261–269, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
24. G. Hornreich, U. Beller, O. Lavie, P. Renbaum, Y. Cohen, and E. Levy-Lahad, “Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature,” Gynecologic Oncology, vol. 75, no. 2, pp. 300–304, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
25. D. A. Levine, O. Lin, R. R. Barakat et al., “Risk of endometrial carcinoma associated with BRCA mutation,” Gynecologic Oncology, vol. 80, no. 3, pp. 395–398, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. M. E. Beiner, A. Finch, B. Rosen et al., “The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study,” Gynecologic Oncology, vol. 104, no. 1, pp. 7–10, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. S. Palomba, A. Falbo, R. Mocciaro, T. Russo, and F. Zullo, “Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs),” Gynecologic Oncology, vol. 112, no. 2, pp. 415–421, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. S. Palomba, A. Falbo, T. Russo, and F. Zullo, “Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer,” Gynecologic Oncology, vol. 114, no. 1, pp. 135–136, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. Y. H. Cho, D. Y. Kim, J. H. Kim, Y. M. Kim, Y. T. Kim, and J. H. Nam, “Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center,” Gynecologic Oncology, vol. 106, no. 3, pp. 585–590, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. M. Malzoni, R. Tinelli, F. Cosentino et al., “Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: a prospective randomized study,” Gynecologic Oncology, vol. 112, no. 1, pp. 126–133, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. R. Tozzi, S. Malur, C. Koehler, and A. Schneider, “Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study,” Journal of Minimally Invasive Gynecology, vol. 12, no. 2, pp. 130–136, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. F. Zullo, S. Palomba, A. Falbo et al., “Laparoscopic surgery vs laparotomy for early stage endometrial cancer: long-term data of a randomized controlled trial,” American Journal of Obstetrics and Gynecology, vol. 200, no. 3, pp. 296–e1, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. J. L. Walker, M. R. Piedmonte, N. M. Spirtos et al., “Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5331–5336, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. I. Kalogiannidis, S. Lambrechts, F. Amant, P. Neven, T. V. Gorp, and I. Vergote, “Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome,” American Journal of Obstetrics and Gynecology, vol. 196, no. 3, pp. 248–e1, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. A. Obermair, T. P. Manolitsas, Y. Leung, I. G. Hammond, and A. J. McCartney, “Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival,” Gynecologic Oncology, vol. 92, no. 3, pp. 789–793, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. A. Obermair, T. P. Manolitsas, Y. Leung, I. G. Hammond, and A. J. Mccartney, “Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer,” International Journal of Gynecological Cancer, vol. 15, no. 2, pp. 319–324, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. W. T. Creasman, C. P. Morrow, B. N. Bundy, H. D. Homesley, J. E. Graham, and P. B. Heller, “Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study,” Cancer, vol. 60, no. 8, pp. 2035–2041, 1987. View at Scopus
38. J. R. Lurain, N. K. Rumsey, J. C. Schink, C. B. Wallemark, and J. S. Chmiel, “Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium,” Obstetrics and Gynecology, vol. 74, no. 2, pp. 175–179, 1989. View at Scopus
39. V. R. Harouny, G. P. Sutton, S. A. Clark, H. E. Geisler, F. B. Stehman, and C. E. Ehrlich, “The importance of peritoneal cytology in endometrial carcinoma,” Obstetrics and Gynecology, vol. 72, no. 3 I, pp. 394–398, 1988. View at Scopus
40. Y. Hirai, I. Fujimoto, K. Yamauchi, K. Hasumi, K. Masubuchi, and Y. Sano, “Peritoneal fluid cytology and prognosis in patients with endometrial carcinoma,” Obstetrics and Gynecology, vol. 73, no. 3 I, pp. 335–338, 1989. View at Scopus
41. J. R. Lurain, “The significance of positive peritoneal cytology in endometrial cancer,” Gynecologic Oncology, vol. 46, no. 2, pp. 143–144, 1992. View at Publisher · View at Google Scholar · View at Scopus
42. N. Takeshima, H. Nishida, T. Tabata, Y. Hirai, and K. Hasumi, “Positive peritoneal cytology in endometrial cancer: enhancement of other prognostic indicators,” Gynecologic Oncology, vol. 82, no. 3, pp. 470–473, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. N. Kadar, H. D. Homesley, and J. H. Malfetano, “Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease,” Gynecologic Oncology, vol. 46, no. 2, pp. 145–149, 1992. View at Publisher · View at Google Scholar · View at Scopus
44. C. P. Morrow, B. N. Bundy, R. J. Kurman et al., “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 40, no. 1, pp. 55–65, 1991. View at Publisher · View at Google Scholar · View at Scopus
45. R. J. Zaino, R. J. Kurman, K. L. Diana, and C. P. Morrow, “Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage—a Gynecologic Oncology Group study,” Cancer, vol. 77, no. 6, pp. 1115–1121, 1996. View at Publisher · View at Google Scholar
46. M. F. Milosevic, A. J. Dembo, and G. M. Thomas, “The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma,” International Journal of Gynecological Cancer, vol. 2, no. 5, pp. 225–235, 1992.
47. Y. Hirai, N. Takeshima, T. Kato, and K. Hasumi, “Malignant potential of positive peritoneal cytology in endometrial cancer,” Obstetrics and Gynecology, vol. 97, no. 5, pp. 725–728, 2001. View at Scopus
48. R. N. Grimshaw, W. C. Tupper, R. C. Fraser, M. G. Tompkins, and J. F. Jeffrey, “Prognostic value of peritoneal cytology in endometrial carcinoma,” Gynecologic Oncology, vol. 36, no. 1, pp. 97–100, 1990. View at Publisher · View at Google Scholar · View at Scopus
49. T. Kasamatsu, T. Onda, N. Katsumata et al., “Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus,” British Journal of Cancer, vol. 88, no. 2, pp. 245–250, 2003. View at Scopus
50. P. M. Tebeu, Y. Popowski, H. M. Verkooijen et al., “Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis,” British Journal of Cancer, vol. 91, no. 4, pp. 720–724, 2004. View at Scopus
51. L. J. Havrilesky, J. M. Cragun, B. Calingaert et al., “The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer,” Gynecologic Oncology, vol. 104, no. 2, pp. 401–405, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. Y. Saga, M. Imai, T. Jobo et al., “Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?” Gynecologic Oncology, vol. 103, no. 1, pp. 277–280, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. J. K. Chan, M. K. Cheung, W. K. Huh et al., “Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients,” Cancer, vol. 107, no. 8, pp. 1823–1830, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. J. G. Aalders and G. Thomas, “Endometrial cancer-Revisiting the importance of pelvic and para aortic lymph nodes,” Gynecologic Oncology, vol. 104, no. 1, pp. 222–231, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. E. L. Trimble, C. Kosary, and R. C. Park, “Lymph node sampling and survival in endometrial cancer,” Gynecologic Oncology, vol. 71, no. 3, pp. 340–343, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. C. V. Lutman, L. J. Havrilesky, J. M. Cragun et al., “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology,” Gynecologic Oncology, vol. 102, no. 1, pp. 92–97, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. H. Kitchener, et al., “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study,” The Lancet, vol. 373, no. 9658, pp. 125–136, 2009.
58. C. L. Creutzberg, W. L.J. Van Putten, P. C.M. Koper et al., “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma,” The Lancet, vol. 355, no. 9213, pp. 1404–1411, 2000.
59. C. L. Creutzberg, W. L. J. Van Putten, C. C. Warlain-Rodenhtiis et al., “Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1234–1241, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. T. Onda, H. Yoshikawa, K. Mizutani et al., “Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy,” British Journal of Cancer, vol. 75, no. 12, pp. 1836–1841, 1997. View at Scopus
61. D. S. McMeekin, D. Lashbrook, M. Gold, G. Johnson, J. L. Walker, and R. Mannel, “Analysis of FIGO stage IIIc endometrial cancer patients,” Gynecologic Oncology, vol. 81, no. 2, pp. 273–278, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
62. G. Nelson, M. Randall, G. Sutton, D. Moore, J. Hurteau, and K. Look, “FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy,” Gynecologic Oncology, vol. 75, no. 2, pp. 211–214, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. B. A. Goff, D. Kato, R. A. Schmidt et al., “Uterine papillary serous carcinoma: patterns of metastatic spread,” Gynecologic Oncology, vol. 54, no. 3, pp. 264–268, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. K. C. Podratz, A. Mariani, and M. J. Webb, “Staging and therapeutic value of lymphadenectomy in endometrial cancer,” Gynecologic Oncology, vol. 70, no. 2, pp. 163–164, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
65. C. Nakagawa-Okamura, S. Sato, I. Tsuji et al., “Effectiveness of mass screening for endometrial cancer,” Acta Cytologica, vol. 46, no. 2, pp. 277–283, 2002. View at Scopus
66. M. Frumovitz, D. K. Singh, L. Meyer et al., “Predictors of final histology in patients with endometrial cancer,” Gynecologic Oncology, vol. 95, no. 3, pp. 463–468, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. A. S. Case, R. P. Rocconi, J. M. Straughn et al., “A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer,” Obstetrics and Gynecology, vol. 108, no. 6, pp. 1375–1379, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. M. Frumovitz, B. M. Slomovitz, D. K. Singh et al., “Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer,” Journal of the American College of Surgeons, vol. 199, no. 3, pp. 388–393, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. P. B. Panici, S. Basile, F. Maneschi et al., “Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial,” Journal of the National Cancer Institute, vol. 100, no. 23, pp. 1707–1716, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
70. H. Nomura, D. Aoki, N. Suzuki et al., “Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer,” International Journal of Gynecological Cancer, vol. 16, no. 2, pp. 799–804, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. A. Mariani, S. C. Dowdy, W. A. Cliby et al., “Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients,” Gynecologic Oncology, vol. 101, no. 2, pp. 200–208, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
72. T. Fujimoto, H. Nanjyo, A. Nakamura et al., “Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer,” Gynecologic Oncology, vol. 107, no. 2, pp. 253–259, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
73. M. Ryan, M. C. Stainton, E. K. Slaytor, C. Jaconelli, S. Watts, and P. Mackenzie, “Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 43, no. 2, pp. 148–151, 2003. View at Publisher · View at Google Scholar · View at Scopus
74. L. C. Kilgore, E. E. Partridge, R. D. Alvarez et al., “Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling,” Gynecologic Oncology, vol. 56, no. 1, pp. 29–33, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
75. A. Chao, T. C. Chang, K. K. Ng et al., “F-FDG PET in the management of endometrial cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 1, pp. 36–44, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
76. H. H. Chung, W. J. Kang, J. W. Kim et al., “The clinical impact of [18F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 6, pp. 1081–1088, 2008. View at Publisher · View at Google Scholar · View at PubMed
77. M. Signorelli, L. Guerra, A. Buda et al., “Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases,” Gynecologic Oncology, vol. 115, no. 2, pp. 231–235, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. K. Kitajima, K. Murakami, E. Yamasaki et al., “Accuracy of18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer,” American Journal of Roentgenology, vol. 190, no. 6, pp. 1652–1658, 2008. View at Publisher · View at Google Scholar · View at PubMed
79. N. S. Horowitz, F. Dehdashti, T. J. Herzog et al., “Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer,” Gynecologic Oncology, vol. 95, no. 3, pp. 546–551, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
80. E. Pelosi, V. Arena, B. Baudino et al., “Preliminary study of sentinel node identification with 99mTc colloid and blue dye in patients with endometrial cancer,” Tumori, vol. 88, no. 3, pp. S9–S10, 2002.
81. E. Barranger, A. Cortez, D. Grahek, P. Callard, S. Uzan, and E. Darai, “Laparoscopic sentinel node procedure using a combination of patent blue and radiocolloid in women with endometrial cancer,” Annals of Surgical Oncology, vol. 11, no. 3, pp. 344–349, 2004. View at Publisher · View at Google Scholar · View at Scopus
82. L. Lelièvre, S. Camatte, M. A. Le Frère-Belda et al., “Sentinel lymph node biopsy in cervical and endometrial cancers: a feasibility study,” Bulletin du Cancer, vol. 91, no. 4, pp. 379–384, 2004. View at Scopus
83. H. Niikura, C. Okamura, H. Utsunomiya et al., “Sentinel lymph node detection in patients with endometrial cancer,” Gynecologic Oncology, vol. 92, no. 2, pp. 669–674, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. M. Maccauro, G. Lucignani, G. Aliberti et al., “Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 5, pp. 569–574, 2005. View at Publisher · View at Google Scholar · View at PubMed
85. J. F. Delaloye, S. Pampallona, E. Chardonnens et al., “Intraoperative lymphatic mapping and sentinel node biopsy using hysteroscopy in patients with endometrial cancer,” Gynecologic Oncology, vol. 106, no. 1, pp. 89–93, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
86. L. A. F. Lopes, S. M. Nicolau, F. F. Baracat et al., “Sentinel lymph node in endometrial cancer,” International Journal of Gynecological Cancer, vol. 17, no. 5, pp. 1113–1117, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
87. M. Frumovitz, D. C. Bodurka, R. R. Broaddus et al., “Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer,” Gynecologic Oncology, vol. 104, no. 1, pp. 100–103, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
88. A. Kong, N. Johnson, P. Cornes et al., “Adjuvant radiotherapy for stage I endometrial cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003916, 2007.
89. A. Kong, I. Simera, M. Collingwood, C. Williams, and H. Kitchener, “Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis,” Annals of Oncology, vol. 18, no. 10, pp. 1595–1604, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
90. H. M. Keys, J. A. Roberts, V. L. Brunetto et al., “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 92, no. 3, pp. 744–751, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
91. D. E. Cohn, E. M. Woeste, S. Cacchio et al., “Clinical and pathologic correlates in surgical stage II endometrial carcinoma,” Obstetrics and Gynecology, vol. 109, no. 5, pp. 1062–1067, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
92. P. J. Rossi, A. B. Jani, I. R. Horowitz, and P. A. S. Johnstone, “Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 1, pp. 134–138, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
93. J. D. Wright, J. Fiorelli, A. L. Kansler et al., “Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation,” American Journal of Obstetrics and Gynecology, vol. 200, no. 4, pp. 419–e1, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
94. N. Johnson and P. Cornes, “Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis,” British Journal of Obstetrics and Gynaecology, vol. 114, no. 11, pp. 1313–1320, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
95. C. M. Lee, A. Szabo, D. C. Shrieve, O. K. Macdonald, and D. K. Gaffney, “Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma,” Journal of the American Medical Association, vol. 295, no. 4, pp. 389–397, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
96. J. K. Chan, H. Wu, M. K. Cheung, J. Y. Shin, K. Osann, and D. S. Kapp, “The outcomes of 27,063 women with unstaged endometrioid uterine cancer,” Gynecologic Oncology, vol. 106, no. 2, pp. 282–288, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
97. B. Sorbe, B. Nordström, J. Mäenpää et al., “Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study,” International Journal of Gynecological Cancer, vol. 19, no. 5, pp. 873–878, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
98. A. E. S. Group, et al., “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis,” The Lancet, vol. 373, no. 9658, pp. 137–146, 2009.
99. R. A. Nout, V. T. H. B. M. Smit, H. Putter et al., “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial,” The Lancet, vol. 375, no. 9717, pp. 816–823, 2010. View at Publisher · View at Google Scholar · View at Scopus
100. R. A. Nout, H. Putter, I. M. Jürgenliemk-Schulz et al., “Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3547–3556, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
101. T. Thigpen, R. B. Vance, L. Balducci, and J. Blessing, “Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma,” Cancer, vol. 48, no. 2, pp. 658–665, 1981. View at Scopus
102. R. Maggi, A. Lissoni, F. Spina et al., “Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial,” British Journal of Cancer, vol. 95, no. 3, pp. 266–271, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
103. N. Susumu, S. Sagae, Y. Udagawa et al., “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at PubMed
104. D. C. Farhi, J. Nosanchuk, and S. G. Silverberg, “Endometrial adenocarcinoma in women under 25 years of age,” Obstetrics and Gynecology, vol. 68, no. 6, pp. 741–745, 1986.
105. R. R. Broaddus, H. T. Lynch, L. M. Chen et al., “Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma,” Cancer, vol. 106, no. 1, pp. 87–94, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
106. W. H. Gotlieb, M. E. Beiner, B. Shalmon et al., “Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer,” Obstetrics and Gynecology, vol. 102, no. 4, pp. 718–725, 2003. View at Publisher · View at Google Scholar
107. C. B. Wang, C. J. Wang, H. J. Huang et al., “Fertility-preserving treatment in young patients with endometrial adenocarcinoma,” Cancer, vol. 94, no. 8, pp. 2192–2198, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
108. K. Yamazawa, M. Hirai, A. Fujito et al., “Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer,” Human Reproduction, vol. 22, no. 7, pp. 1953–1958, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
109. K. Niwa, K. Tagami, Z. Lian, K. Onogi, H. Mori, and T. Tamaya, “Outcome of fertility-preserving treatment in young women with endometrial carcinomas,” British Journal of Obstetrics and Gynaecology, vol. 112, no. 3, pp. 317–320, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
110. T. Ota, M. Yoshida, M. Kimura, and K. Kinoshita, “Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger,” International Journal of Gynecological Cancer, vol. 15, no. 4, pp. 657–662, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
111. G. Gitsch, E. Hanzal, D. Jensen, and N. F. Hacker, “Endometrial cancer in premenopausal women 45 years and younger,” Obstetrics and Gynecology, vol. 85, no. 4, pp. 504–508, 1995. View at Publisher · View at Google Scholar
112. C. Walsh, C. Holschneider, Y. Hoang, K. Tieu, B. Karlan, and I. Cass, “Coexisting ovarian malignancy in young women with endometrial cancer,” Obstetrics and Gynecology, vol. 106, no. 4, pp. 693–699, 2005.